Bellicum Pharmaceuticals Stock Earnings Per Share
| BLCMDelisted Stock | USD 0.37 0.05 11.90% |
Bellicum Pharmaceuticals fundamentals help investors to digest information that contributes to Bellicum Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Bellicum Pink Sheet. The fundamental analysis module provides a way to measure Bellicum Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellicum Pharmaceuticals pink sheet.
Bellicum |
Bellicum Pharmaceuticals Company Earnings Per Share Analysis
Bellicum Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Bellicum Pharmaceuticals Earnings Per Share | (1.57) X |
Most of Bellicum Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellicum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Bellicum Pharmaceuticals has an Earnings Per Share of -1.57 times. This is 118.76% lower than that of the Biotechnology sector and 67.22% lower than that of the Health Care industry. The earnings per share for all United States stocks is 150.32% higher than that of the company.
Bellicum Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellicum Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellicum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Bellicum Pharmaceuticals by comparing valuation metrics of similar companies.Bellicum Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Bellicum Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (19.69) % | |||
| Current Valuation | (38.62 M) | |||
| Shares Outstanding | 9.5 M | |||
| Shares Owned By Insiders | 4.19 % | |||
| Shares Owned By Institutions | 29.30 % | |||
| Number Of Shares Shorted | 1.44 M | |||
| Price To Earning | 8.50 X | |||
| Price To Book | 1.00 X | |||
| Price To Sales | 5.46 X | |||
| Revenue | 1.5 M | |||
| Gross Profit | (17.38 M) | |||
| EBITDA | (28.93 M) | |||
| Net Income | (24.97 M) | |||
| Cash And Equivalents | 33.17 M | |||
| Cash Per Share | 3.85 X | |||
| Total Debt | 58 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.07 X | |||
| Book Value Per Share | (1.11) X | |||
| Cash Flow From Operations | (25.78 M) | |||
| Short Ratio | 0.17 X | |||
| Earnings Per Share | (1.57) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.57 | |||
| Market Capitalization | 3.52 M | |||
| Total Asset | 23.82 M | |||
| Retained Earnings | (575.42 M) | |||
| Working Capital | 20.03 M | |||
| Current Asset | 96.89 M | |||
| Current Liabilities | 7.45 M | |||
| Z Score | -0.31 | |||
| Net Asset | 23.82 M |
About Bellicum Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bellicum Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellicum Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellicum Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Bellicum Pink Sheet
If you are still planning to invest in Bellicum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellicum Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |